Immunovant, Inc. IMVT Other accrued liabilities
Other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrent.
The official record: Immunovant, Inc.’s 10-Q, filed February 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunovant, Inc.'s other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunovant, Inc.'s other accrued liabilities?
- Immunovant, Inc. (IMVT) reported other accrued liabilities of $2.41M in Q4 2025.
- How has Immunovant, Inc.'s other accrued liabilities changed year-over-year?
- Immunovant, Inc.'s other accrued liabilities increased by 58.0% year-over-year, from $1.52M to $2.41M.
- What is the long-term trend for Immunovant, Inc.'s other accrued liabilities?
- Over 4 years (2021 to 2025), Immunovant, Inc.'s other accrued liabilities has grown at a 23.0% compound annual growth rate (CAGR), from $679K to $1.55M.